Why did JNJ's reported GAAP earnings fall so sharply for Q1 2024?

The proposed talc Plan of Reorganization is treated as a recognized subsequent event, so the company recorded an incremental $2.7 billion litigation charge in Q1 2024. This reduced GAAP net earnings from $5.4 billion to $3.3 billion and GAAP diluted EPS from $2.20 to $1.34. Adjusted EPS of $2.71 is unaffected because the company excludes litigation charges from its non-GAAP measures.

How much will Johnson & Johnson ultimately pay to resolve the ovarian talc claims?

The company commits to a present value of about $6.475 billion, paid over 25 years, which equals a nominal value of about $8.4 billion discounted at 4.4%. The total reserve recorded is about $11.0 billion present value ($13.7 billion nominal). The filing notes that the company cannot predict the ultimate financial outcome of its litigation.

What must happen for the proposed talc plan to proceed?

The plan includes a three-month solicitation period in which ovarian claimants can vote. If 75% of claimants vote in favor, a Company subsidiary may file a consensual prepackaged Chapter 11 bankruptcy to secure confirmation. The company says it will also keep pursuing appeals, tort-system litigation, and a Daubert review of plaintiffs' expert opinions in the MDL.

Does the talc settlement affect Johnson & Johnson's underlying business performance?

Not directly. Q1 2024 sales grew 2.3% to $21.4 billion, gross margin rose to 69.6%, and adjusted EPS grew 12.4% to $2.71. The litigation charge is excluded from adjusted measures, so the operational picture is stronger than the GAAP results suggest. The 25-year payment schedule is a long-term cash obligation that investors will need to monitor.

What claims are excluded from the proposed talc plan?

The plan does not cover mesothelioma claims or state consumer protection claims. The company says it has already resolved about 95% of mesothelioma lawsuits filed to date, and it has agreements in principle to address the state consumer protection claims separately. It has also reached an agreement in principle to resolve talc-related claims in the bankruptcy cases of its talc suppliers, Imerys and Cyprus.

JNJ 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed May 1, 2024. Cited figures are marked; the original filing is the authoritative source.

Johnson & Johnson's May 1, 2024 8-K reports first-quarter 2024 results and a major legal development.

The company announced a proposed Plan of Reorganization, run through its subsidiary LLT Management LLC, to resolve all current and future U.S. ovarian cancer cosmetic talc claims. The company will pay a present value of about $6.475 billion^a (nominal about $8.4 billion) over 25 years, discounted at 4.4%. It recorded an incremental $2.7 billion litigation charge, bringing its total talc reserve to about $11 billion present value ($13.7 billion nominal).

Because the plan is a recognized subsequent event, GAAP net earnings for Q1 2024 fall from $5.4 billion to $3.3 billion^b, and GAAP EPS falls from $2.20 to $1.34. Underlying operations were solid. Sales rose 2.3% to $21.4 billion, and adjusted EPS grew 12.4% to $2.71 from $2.41, with operational adjusted EPS of $2.72.

Adjusted figures are unaffected by the litigation charge, so investors should weigh the GAAP hit as largely a one-time, non-cash-in-period reserve rather than a change in run-rate earnings. The company also disclosed that the plan would resolve 99.75%^c of pending U.S. talc lawsuits, that a three-month claimant vote is planned with 75% approval needed to proceed, and that mesothelioma and state consumer protection claims will be handled separately. Management maintains that the claims lack merit and that it will pursue parallel litigation pathways.

For investors, the central questions are whether the 75%^d claimant vote succeeds and whether the Daubert review of plaintiffs' expert opinions in the MDL goes in the company's favor. Both could materially change the final cost of the talc exposure. The 25-year payment schedule also creates a long-dated liability that will weigh on the balance sheet and cash flow.

02—Key points

Key Highlights

Proposed talc plan: LLT Management LLC proposes to resolve all current and future U.S. ovarian cancer cosmetic talc claims for a present value of about $6.475 billion (nominal about $8.4 billion) paid over 25 years.
Litigation charge: An incremental $2.7 billion charge brings the total talc reserve to about $11.0 billion present value ($13.7 billion nominal).
GAAP earnings restated: Q1 2024 GAAP net earnings fall from $5.4 billion to $3.3 billion, and GAAP diluted EPS falls from $2.20 to $1.34, because the plan is treated as a recognized subsequent event.
Q1 2024 operations: Sales rose 2.3% to $21.4 billion, gross margin improved to 69.6% from 68.0%, and Innovative Medicine adjusted pre-tax margin was 42.9%.
Adjusted EPS strength: Adjusted diluted EPS grew 12.4% to $2.71 from $2.41, with operational adjusted EPS of $2.72; these measures exclude the talc charge.
Plan scope: The plan covers about 99.75% of pending U.S. talc lawsuits, while mesothelioma (about 95% already resolved) and state consumer protection claims are addressed outside the plan.
Approval path: A three-month claimant solicitation period is planned, and 75% claimant approval would allow a subsidiary to file a prepackaged Chapter 11 case, with parallel litigation pathways still pursued.

03—Questions

Frequently Asked Questions

Why did JNJ's reported GAAP earnings fall so sharply for Q1 2024?
The proposed talc Plan of Reorganization is treated as a recognized subsequent event, so the company recorded an incremental $2.7 billion litigation charge in Q1 2024. This reduced GAAP net earnings from $5.4 billion to $3.3 billion and GAAP diluted EPS from $2.20 to $1.34. Adjusted EPS of $2.71 is unaffected because the company excludes litigation charges from its non-GAAP measures.
How much will Johnson & Johnson ultimately pay to resolve the ovarian talc claims?
The company commits to a present value of about $6.475 billion, paid over 25 years, which equals a nominal value of about $8.4 billion discounted at 4.4%. The total reserve recorded is about $11.0 billion present value ($13.7 billion nominal). The filing notes that the company cannot predict the ultimate financial outcome of its litigation.
What must happen for the proposed talc plan to proceed?
The plan includes a three-month solicitation period in which ovarian claimants can vote. If 75% of claimants vote in favor, a Company subsidiary may file a consensual prepackaged Chapter 11 bankruptcy to secure confirmation. The company says it will also keep pursuing appeals, tort-system litigation, and a Daubert review of plaintiffs' expert opinions in the MDL.
Does the talc settlement affect Johnson & Johnson's underlying business performance?
Not directly. Q1 2024 sales grew 2.3% to $21.4 billion, gross margin rose to 69.6%, and adjusted EPS grew 12.4% to $2.71. The litigation charge is excluded from adjusted measures, so the operational picture is stronger than the GAAP results suggest. The 25-year payment schedule is a long-term cash obligation that investors will need to monitor.
What claims are excluded from the proposed talc plan?
The plan does not cover mesothelioma claims or state consumer protection claims. The company says it has already resolved about 95% of mesothelioma lawsuits filed to date, and it has agreements in principle to address the state consumer protection claims separately. It has also reached an agreement in principle to resolve talc-related claims in the bankruptcy cases of its talc suppliers, Imerys and Cyprus.

04—Continue

← View all 8-K filings